Magenta therapeutics announces multiple presentations across stem cell transplant portfolio at the american society of hematology (ash) annual meeting

Cambridge, mass.--(business wire)--magenta therapeutics (nasdaq: mgta), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that data across the portfolio will be presented at the american society of hematology (ash) annual meeting, to be held december 5-8, 2020. “these data demonstrate the progress of our clinical and preclinical pipeline to expand patient eligibility to safely and effectively b
DNTH Ratings Summary
DNTH Quant Ranking